FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012476302> ?p ?o ?g. }

• W2012476302 endingPage "235" @default.
• W2012476302 startingPage "229" @default.
• W2012476302 abstract "We investigated the serum concentration of endostatin in 84 patients with multiple myeloma (MM) and in 13 healthy controls. The level of measured anti-angiogenic agent was correlated with the phase and stage of the disease, and most importantly with clinical and laboratory parameters depicting the disease activity (haemoglobin, creatinine, albumins, calcium, M-component, C-reactive protein, beta2-microglobulin, lactate dehydrogenase, stage of bone disease) as well as serum levels of pro-angiogenic cytokines such as vascular endothelial growth factor, hepatocyte growth factor, fibroblast growth factor and transforming growth factor-beta. The median serum level of endostatin in MM patients was 58 ng/ml and was statistically significantly higher than in the control group (median, 40 ng/ml; p=0.015). MM patients in phase I (at diagnosis) had higher levels of endostatin (median, 69 ng/ml) than those in phase II (plateau phase after treatment) (median, 49 pg/ml; p=0.044). We did not find any statistical correlation between the level of endostatin and stage of MM according to the Durie and Salmon system. The serum concentration of endostatin in MM patients with a normal level of albumins was significantly higher than in others with hypoalbuminaemia (median, 62 ng/ml versus 39 ng/ml; p=0.033). Also, patients with a normal value of lactate dehydrogenase had a higher concentration of endostatin than those with values >425 U/l (median, 70 ng/ml versus 39 ng/ml; p=0.019). We did not show any statistical correlation between the concentration of endostatin and level of haemoglobin, creatinine, calcium, C-reactive protein, beta2-microglobulin and stage of bone disease. We failed to find positive or negative correlations between the level of endostatin and vascular endothelial growth factor, hepatocyte growth factor, fibroblast growth factor and transforming growth factor-beta. The concentration of endostatin did not influence the probability of survival in MM patients in our study. In conclusion, our data indicate that endostatin has a higher level in MM patients than in healthy controls. Highest values were stated in active phases of the disease (at presentation and in progression). Different clinical and laboratory parameters generally do not influence the concentration of endostatin (except albumins and lactate dehydrogenase)." @default.
• W2012476302 created "2016-06-24" @default.
• W2012476302 creator A5008139866 @default.
• W2012476302 creator A5069332579 @default.
• W2012476302 date "2003-01-01" @default.
• W2012476302 modified "2023-10-16" @default.
• W2012476302 title "High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment" @default.
• W2012476302 cites W1487159685 @default.
• W2012476302 cites W1489780573 @default.
• W2012476302 cites W1569373357 @default.
• W2012476302 cites W1658860190 @default.
• W2012476302 cites W1779581082 @default.
• W2012476302 cites W1968431199 @default.
• W2012476302 cites W1971149609 @default.
• W2012476302 cites W1972461194 @default.
• W2012476302 cites W1985804036 @default.
• W2012476302 cites W1989772702 @default.
• W2012476302 cites W1991033490 @default.
• W2012476302 cites W1998909889 @default.
• W2012476302 cites W2006382315 @default.
• W2012476302 cites W2019883573 @default.
• W2012476302 cites W2021510332 @default.
• W2012476302 cites W2031897417 @default.
• W2012476302 cites W2041116703 @default.
• W2012476302 cites W2071080900 @default.
• W2012476302 cites W2085396553 @default.
• W2012476302 cites W2108786375 @default.
• W2012476302 cites W2131798870 @default.
• W2012476302 cites W2140724459 @default.
• W2012476302 cites W2150048971 @default.
• W2012476302 cites W2161659842 @default.
• W2012476302 cites W2168994455 @default.
• W2012476302 cites W2169926915 @default.
• W2012476302 cites W2204572831 @default.
• W2012476302 cites W2325441863 @default.
• W2012476302 cites W2333546805 @default.
• W2012476302 cites W2419487429 @default.
• W2012476302 cites W72033272 @default.
• W2012476302 doi "https://doi.org/10.1080/09629350310001599675" @default.
• W2012476302 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1781619" @default.
• W2012476302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14514474" @default.
• W2012476302 hasPublicationYear "2003" @default.
• W2012476302 type Work @default.
• W2012476302 sameAs 2012476302 @default.
• W2012476302 citedByCount "15" @default.
• W2012476302 countsByYear W20124763022012 @default.
• W2012476302 countsByYear W20124763022013 @default.
• W2012476302 countsByYear W20124763022015 @default.
• W2012476302 countsByYear W20124763022017 @default.
• W2012476302 countsByYear W20124763022019 @default.
• W2012476302 countsByYear W20124763022021 @default.
• W2012476302 crossrefType "journal-article" @default.
• W2012476302 hasAuthorship W2012476302A5008139866 @default.
• W2012476302 hasAuthorship W2012476302A5069332579 @default.
• W2012476302 hasBestOaLocation W20124763021 @default.
• W2012476302 hasConcept C126322002 @default.
• W2012476302 hasConcept C134018914 @default.
• W2012476302 hasConcept C167734588 @default.
• W2012476302 hasConcept C170493617 @default.
• W2012476302 hasConcept C181199279 @default.
• W2012476302 hasConcept C185592680 @default.
• W2012476302 hasConcept C21957315 @default.
• W2012476302 hasConcept C2776125364 @default.
• W2012476302 hasConcept C2776364478 @default.
• W2012476302 hasConcept C2776996007 @default.
• W2012476302 hasConcept C2777025900 @default.
• W2012476302 hasConcept C2777318727 @default.
• W2012476302 hasConcept C2780306776 @default.
• W2012476302 hasConcept C2780394083 @default.
• W2012476302 hasConcept C55493867 @default.
• W2012476302 hasConcept C71924100 @default.
• W2012476302 hasConcept C75920679 @default.
• W2012476302 hasConcept C90924648 @default.
• W2012476302 hasConceptScore W2012476302C126322002 @default.
• W2012476302 hasConceptScore W2012476302C134018914 @default.
• W2012476302 hasConceptScore W2012476302C167734588 @default.
• W2012476302 hasConceptScore W2012476302C170493617 @default.
• W2012476302 hasConceptScore W2012476302C181199279 @default.
• W2012476302 hasConceptScore W2012476302C185592680 @default.
• W2012476302 hasConceptScore W2012476302C21957315 @default.
• W2012476302 hasConceptScore W2012476302C2776125364 @default.
• W2012476302 hasConceptScore W2012476302C2776364478 @default.
• W2012476302 hasConceptScore W2012476302C2776996007 @default.
• W2012476302 hasConceptScore W2012476302C2777025900 @default.
• W2012476302 hasConceptScore W2012476302C2777318727 @default.
• W2012476302 hasConceptScore W2012476302C2780306776 @default.
• W2012476302 hasConceptScore W2012476302C2780394083 @default.
• W2012476302 hasConceptScore W2012476302C55493867 @default.
• W2012476302 hasConceptScore W2012476302C71924100 @default.
• W2012476302 hasConceptScore W2012476302C75920679 @default.
• W2012476302 hasConceptScore W2012476302C90924648 @default.
• W2012476302 hasFunder F4320323482 @default.
• W2012476302 hasIssue "4" @default.
• W2012476302 hasLocation W20124763021 @default.
• W2012476302 hasLocation W20124763022 @default.
• W2012476302 hasLocation W20124763023 @default.
• W2012476302 hasLocation W20124763024 @default.
• W2012476302 hasLocation W20124763025 @default.

• next